Armata Pharmctcl (ARMP) Stock News

Armata Pharmaceuticals (NYSE American: ARMP) announced formal commissioning of its new cGMP phage manufacturing facility in Los Angeles on November 10, 2025. The 56,000 sq ft site includes 10,000 sq ft of cGMP clean rooms, an automated fill-and-finish suite, quality control and R&D labs, and administrative space. The company notified the FDA that production has commenced and completed full production runs with no issues. The facility is positioned to supply high-purity multi-phage cocktails for clinical programs and to support a potential Phase 3 AP-SA02 trial planned for 2026, subject to FDA review, plus future commercial and contract manufacturing opportunities.

Armata Pharmaceuticals (NYSE American: ARMP) reported positive Phase 2a diSArm results for IV bacteriophage cocktail AP-SA02 in complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025 on Oct 22, 2025. The randomized, double-blind trial enrolled 42 patients (29 AP-SA02 + BAT; 13 placebo + BAT).

Day 12 clinical response: 88% vs 58% (PI assessment, p=0.047); adjudicator assessment 83% vs 58%. Non-response/relapse at one week post-BAT and at EOS: 0% AP-SA02 vs ~25% placebo (p-values 0.017–0.025). AP-SA02 was well tolerated; no serious adverse events related to drug. Armata plans a Phase 3 superiority trial in 2026, subject to FDA feedback.

Armata Pharmaceuticals (NYSE American: ARMP) will present late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail AP-SA02 at IDWeek 2025 in Atlanta, GA.

The oral presentation, titled "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia," will be given by Dr. Loren G. Miller on Wednesday, October 22, 2025, from 10:30 AM to 11:45 AM ET in room B401-B402 during the session "Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections."

Armata Pharmaceuticals (NYSE American: ARMP) announced the publication of a research paper in the Journal of Molecular Biology detailing the structural analysis of phage Pa223, a component of their clinical candidate AP-PA02. The study provides the first structural description of a phage from the Bruynoghevirus genus using advanced cryogenic electron microscopy.

AP-PA02, a five-phage cocktail, is being developed to treat chronic respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis (NCFB) patients. The therapeutic has demonstrated promising results in two Phase 2 clinical trials - SWARM-P.a. and Tailwind. The structural insights gained from this research may inform future development of phage-based therapeutics.

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company developing bacteriophage therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Deborah Birx, M.D. will deliver a corporate presentation on September 10, 2025, from 1:30-2:00 PM ET in New York. The company specializes in developing treatments for antibiotic-resistant and difficult-to-treat bacterial infections.

Armata Pharmaceuticals (NYSE American: ARMP) announced significant Q2 2025 developments, including a $15 million secured credit agreement with Innoviva and positive topline results from their Phase 1b/2a diSArm trial for AP-SA02, their lead S. aureus therapeutic candidate.

The company reported Q2 2025 financial results with grant revenue of $2.2 million, R&D expenses of $6.4 million, and cash position of $4.3 million. Additionally, Armata received $4.65 million in non-dilutive funding from the U.S. Department of Defense.

The diSArm trial met all primary endpoints, demonstrating improved clinical outcomes compared to standard antibiotic therapy with no treatment-related serious adverse events. Armata plans to initiate a Phase 3 pivotal trial in 2026 following an FDA end-of-Phase 2 meeting later this year.

Armata Pharmaceuticals (NYSE: ARMP) announced positive topline results from its Phase 1b/2a diSArm trial evaluating AP-SA02, an intravenous bacteriophage therapeutic for treating Staphylococcus aureus bacteremia. The study met all primary endpoints, with AP-SA02 showing significantly improved clinical outcomes compared to best available antibiotic therapy (BAT). Key findings include: - 88% responder rate in AP-SA02 treated subjects vs 58% for placebo at Test of Cure day 12 - 100% clinical response in AP-SA02 group vs 75% in placebo group at end of study - Effective against both MRSA and MSSA infections - No serious treatment-related adverse events observed - Successful manufacturing capacity of over 10,000 full treatment courses annually The trial represents a breakthrough in phage therapy for systemic infections, demonstrating both safety and efficacy in a randomized controlled setting.

Armata Pharmaceuticals (NYSE: ARMP) reported its Q1 2025 financial results and corporate updates. The company anticipates topline results from its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia in H1 2025. Key financial highlights include: revenue of $0.5 million (down from $1.0M in Q1 2024), net loss of $6.5 million ($0.18 per share), and cash position of $11.7 million. The company secured additional funding through a $4.65 million non-dilutive DoD award and a $10 million secured credit agreement with Innoviva. R&D expenses decreased to $5.4 million from $8.0 million year-over-year, while G&A expenses remained relatively stable at $3.3 million.

Armata Pharmaceuticals (NYSE: ARMP) has received an additional $4.65 million in non-dilutive funding from the Department of Defense, bringing the total award to $26.2 million. The funding supports the development of AP-SA02, a phage-based treatment for complicated Staphylococcus aureus bacteremia (SAB). The Phase 1b/2a diSArm trial, which completed enrollment of 50 subjects in November 2024, evaluated AP-SA02 as an adjunct to best available antibiotic therapy. The study successfully achieved dose escalation to 5e10 PFU every six hours without significant adverse events. Notably, approximately half of the treated group showed evidence of phage persistence in blood, suggesting successful targeting of SAB reservoirs. Topline data is expected in Q2 2025, which will inform the optimal dosing for future pivotal trials.